NIJMEGEN –December 15, 2014 ‐ Khondrion, The Netherlands based biopharmaceutical company developing a treatment for mitochondrial disease, announced today the appointment of dr. Edwin Spaans, former director Clinical Development of Kinesis, as its new Chief Medical Officer. Dr. Spaans will be responsible for Khondrion’s clinical trial program of its frontrunner compound KH176. Dr.Spaans will start at Khondrion January 1st 2015.
In a first response to his appointment Edwin Spaans states: “Khondrion has the potential to become a world leading company in the development of new and clinical effective therapies for mitochondrial disorders: innovative Technologies, an extensive portfolio of new chemical entities, a strong international team of employees and a strategic partnership with the Nijmegen Center for Mitochondrial Disorders of the Radboudumc. Khondrion’s Team is devoted to develop a cure for mitochondrial disease. Everyone would love to work for such a dedicated company”.
Jan Smeitink, Khondrion’s Founder and CEO says: “We are extremely proud to have Edwin appointed at Khondrion. Edwin’s expertise will be instrumental in the further development of our drugs of which the first compound ‐ KH176 ‐ will enroll the clinical trial phase Q2‐3 2015. Patients with mitochondrial disease suffer from progressive diseases and with an often early fatal outcome. Our goal is to stop the progression of these diseases and if possible to cure them”. Edwin Spaans served since 2008 as Director Clinical Development at Kinesis.
